Iqvia Holdings Inc 8-K, filed Sep 26, 2023
Iqvia Holdings Inc. (IQV)
About this 8-K
Iqvia Holdings Inc filed this 8-K on September 26, 2023, reporting on events of September 24, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 26, 2023 (
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class |
Trading Symbol |
Name of Each Exchange on which Registered | ||
| “ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Appointment of Richard Staub III as President, Research & Development Solutions
On September 25, 2023, IQVIA Holdings Inc. (the “Company”) announced the appointment of Richard Staub III to serve as President of its Research & Development Solutions (“R&DS”) business unit, effective September 25, 2023. Mr. Staub brings thirty-four years of relevant industry experience to this role.
Mr. Staub previously served as the President of the R&DS business unit from 2016 to 2022. Mr. Staub then served as a senior advisor to the Company’s Chairman and CEO, where he worked closely with the R&DS business, having responsibility for key customer relationships, providing leadership on critical business issues and continuing to guide the overall strategic direction of the business.
Departure of Costa Panagos, President, Research & Development Solutions
On September 24, 2023, Costa Panagos informed the Company of his intention to leave the Company. His last day was September 25, 2023.
Under the terms of his Confidentiality and Restrictive Covenants Agreement with the Company, Mr. Panagos is subject to noncompetition and nonsolicitation covenants for a period of 12 months following the termination of his employment.
| Item 7.01. | Regulation FD Disclosure. |
On September 25, 2023, the Company issued a press release announcing Mr. Staub’s appointment and Mr. Panagos’ departure from the Company, which is attached hereto as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
| Exhibit |
Description | |
| 99.1 | Press release dated September 25, 2023 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 26, 2023
| IQVIA HOLDINGS INC. | ||
| By: | /s/ Eric M. Sherbet | |
| Eric M. Sherbet | ||
| Executive Vice President, General Counsel and Secretary | ||
Exhibit 99.1
NEWS
| Contact: | Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com) | |
| +1.973.316.3828 | ||
| Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com) | ||
| +1.919.780.3221 | ||
IQVIA Appoints Richard Staub III President of Research & Development Solutions
RESEARCH TRIANGLE PARK, N.C. – September 25, 2023 – IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit.
Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consecutive years of record-breaking backlog, posted industry leading book to bill ratios and significantly increased R&DS revenues. During his tenure Richard oversaw the rapid expansion of IQVIA’s clinical research capabilities and, critically, he successfully led this business unit through the unprecedented challenges of the COVID-19 global pandemic.
In his role as senior advisor to the Chairman and CEO of IQVIA, Richard worked closely with the R&DS team and was instrumental in R&DS’ continued success. He had responsibility for key customer relationships, provided leadership on critical business issues and continued to guide the overall strategic direction of the business.
Costa Panagos will be retiring from the organization after a 24-year career at IQVIA, where he held several positions including most recently the R&DS business unit leadership role since 2022. IQVIA would like to thank Costa for the contributions he has made to the R&DS organization over this period.
To learn more about IQVIA, visit IQVIA.com for more information.
###
1
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
2